Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.

B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects

Open access
Wu, Fengping, Gao, Jinfang, Kang, Jie, Wang, Xuexue, Niu, Qing, Liu, Jiaxi, Zhang, Liyun·2021·Frontiers in Immunology

Abstract

Rheumatoid arthritis (RA) is a common, chronic, systemic autoimmune disease, and its clinical features are the proliferation of joint synovial tissue, the formation of pannus and the destruction of cartilage. The global incidence of RA is about 1%, and it is more common in women. The basic feature of RA is the body’s immune system disorders, in which autoreactive CD4+T cells, pathogenic B cells, M1 macrophages, inflammatory cytokines, chemokines and autoantibodies abnormally increase in the body of RA patients B cell depletion therapy has well proved the important role of B cells in the pathogenesis of RA, and the treatment of RA with B cells as a target has also been paid more and more attention. Although the inflammatory indicators in RA patients receiving B-cell depletion therapy have been significantly improved, the risk of infection and cancer has also increased, which suggests that we need to deplete pathogenic B cells instead of all B cells. However, at present we cannot distinguish between pathogenic B cells and protective B cells in RA patients. In this review, we explore fresh perspectives upon the roles of B cells in the occurrence, development and treatment of RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.750753

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 133 references

Research works printed but not linked: 15

  1. Zhang, 2021, BAFF, Involved in B Cell Activation Through the NF-kappaB Pathway, Is Related to Disease Activity and Bone Destruction in Rheumatoid Arthritis, Acta Pharmacol Sin, 10.1038/s41401-020-00582-4 · doi:10.1038/s41401-020-00582-4
  2. Zhao, 2014, The Role of a Proliferation-Inducing Ligand (APRIL) in the Pathogenesis of Rheumatoid Arthritis, Scand J Rheumatol, 43, 10.3109/03009742.2014.905630 · doi:10.3109/03009742.2014.905630
  3. Wu, 2020, Nanoparticle-Facilitated Delivery of BAFF-R siRNA for B Cell Intervention and Rheumatoid Arthritis Therapy, Int Immunopharmacol, 88, 106933, 10.1016/j.intimp.2020.106933 · doi:10.1016/j.intimp.2020.106933
  4. Dam, 2018, Increased Binding of Specificity Protein 1 to the IL21R Promoter in B Cells Results in Enhanced B Cell Responses in Rheumatoid Arthritis, Front Immunol, 9, 10.3389/fimmu.2018.01978 · doi:10.3389/fimmu.2018.01978
  5. Kleinau, 2003, The Impact of Fc Receptors on the Development of Autoimmune Diseases, Curr Pharm Des, 9, 10.2174/1381612033454414 · doi:10.2174/1381612033454414
  6. Hu, 2021, Yishen-Tongbi Decoction Inhibits Excessive Activation of B Cells by Activating the FcgammaRIIb/Lyn/SHP-1 Pathway and Attenuates the Inflammatory Response in CIA Rats, BioMed Pharmacother, 134, 111166, 10.1016/j.biopha.2020.111166 · doi:10.1016/j.biopha.2020.111166
  7. Sauer, 2012, Defective B Cell Tolerance in Adenosine Deaminase Deficiency Is Corrected by Gene Therapy, J Clin Invest, 122, 10.1172/JCI61788 · doi:10.1172/jci61788
  8. Detanico, 2013, Somatic Mutagenesis in Autoimmunity, Autoimmunity, 46, 10.3109/08916934.2012.757597 · doi:10.3109/08916934.2012.757597
  9. Malmstrom, 2018, The Parallel Worlds of ACPA-Positive and RF-Positive B Cells, Nat Rev Rheumatol, 14, 10.1038/s41584-018-0094-5 · doi:10.1038/s41584-018-0094-5
  10. Auger, 2020, Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model, Arthritis Rheumatol, 72, 10.1002/art.41189 · doi:10.1002/art.41189
  11. Chirivi, 2013, Anti-Citrullinated Protein Antibodies as Novel Therapeutic Drugs in Rheumatoid Arthritis, J Clin Cell Immunol, 1, 10.4172/2155-9899.S6-006 · doi:10.4172/2155-9899.s6-006
  12. Usha, 2017, In Vitro Allogeneic Immune Cell Response to Mesenchymal Stromal Cells Derived From Human Adipose in Patients With Rheumatoid Arthritis, Cell Immunol, 314, 18, 10.1016/j.cellimm.2017.01.008 · DOI
  13. Noguchi, 2020, Anti-Cyclic Citrullinated Peptide Antibody Titers Decrease in Rheumatoid Arthritis Patients Treated With Tocilizumab: A Pilot Study, Mod Rheumatol, 30, 10.1080/14397595.2019.1583784 · doi:10.1080/14397595.2019.1583784
  14. Martina, 2016, Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro, Transplant Proc, 48, 10.1016/j.transproceed.2016.07.052 · doi:10.1016/j.transproceed.2016.07.052
  15. Sonomoto, 2014, Effects of Tofacitinib on Lymphocytes in Rheumatoid Arthritis: Relation to Efficacy and Infectious Adverse Events, Rheumatol (Oxford), 53, 10.1093/rheumatology/ket466 · doi:10.1093/rheumatology/ket466

Cited by

See all 267

Metadata

Authors
Wu, F., Gao, J., Kang, J., Wang, X., Niu, Q., Liu, J., & Zhang, L.
Venue
Frontiers in Immunology
Published
2021-09-28
Volume
12
Pages
750753-750753
ISSN
1664-3224 (ISSN-L)
OpenAlex
W3204655672
Cited by
267
References
133
FWCI
23.27
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects. https://app.cochat.ai/papers/10.3389/fimmu.2021.750753
The paper
Wu, F., Gao, J., Kang, J., Wang, X., Niu, Q., Liu, J., & Zhang, L. (2021). B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.750753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.